Key Takeaways
- Revenue crossed ₹200 cr, up 23%: EBITDA and PAT each rose over 70%, setting a base for the next two years’ ₹300 cr and ₹500 cr targets.
- The hospital engine has started but is not yet contributing: The first 30-bed facility is operational but below 10% occupancy, awaiting government empanelment and insurance tie-ups; break-even is expected by end of May or June.
- A partnership with Jeena Sikho unlocks beds without heavy capex: The collaboration gives Sat Kartar access to 2,800 North Indian beds for revenue share and a management-fee model to open 150–200 South Indian beds this year, keeping all 300 beds under the Sat Kartar fold.
- Cash generation lagged PAT in H1 but is improving: Working capital was strained by the factory build, Plantomed acquisition and inventory buildup; management says H2 ratios improved and the worst is behind.
- What to watch next quarter: Whether the Delhi hospital reaches break-even, finalisation of Jeena Sikho hospital locations and terms, and RBI approval for the US subsidiary.
The Dual-Engine Shift: Product Company Plus Hospitals
- Core product business remains primary: Management explicitly stated the company will “definitely remain as a product company primarily” while building a healthcare ecosystem around it.
- First hospital is live but nascent: The 30-bed Delhi facility has been running only 40 days, has not crossed 10% occupancy, and is still securing government empanelment and insurance tie-ups; break-even is targeted for late May or June.
- 300 beds targeted by FY27 end, zero revenue assumed this year: The ₹300 cr FY27 revenue target excludes any hospital contribution; hospital revenue flows only in the following year.
- 1,000 beds by FY28 is the ambition: Management is thinking about 1,000 beds, funded first by the ₹45 cr cash in bank, then by hospital and company cash generation, with debt filling any shortfall; no further equity dilution is planned.
- Bed economics and timeline: Facilities of 50–100 beds each, costing ~₹6–7L per bed; once locations are finalised, interiors take six months and licensing up to two months, so roughly eight months to operational.
- Occupancy expectations are high but unproven: Management cited 60–70% occupancy as achievable depending on territory, though the first hospital is still in single digits.
Manprit Singh Chadha: “We were a product company, categorized as a product company. We will definitely remain as a product company primarily, but yes, are moving into a whole fledged ecosystem, into the complete sphere of the healthcare of Ayurveda.”
The Jeena Sikho Partnership
- Structure is a revenue-share and management-fee model, not a JV: In North India, Sat Kartar passes customer inquiries to Jeena Sikho’s 2,800 beds and earns a revenue share; in South India, Sat Kartar opens hospitals under its own name, with Jeena Sikho providing expertise for a management fee.
- Customer data and recurring revenue rights are protected: In the South, customer data stays with Sat Kartar; in the North, Sat Kartar has a contractual right to a percentage of future recurring revenue from the customers it refers, and cannot divert them to competitors.
- Hospital branding will be co-branded in the South: Facilities may carry the name “Sat Kartar Hospital co-powered with Jeena Sikho.”
- Product cross-utilisation is being built: Hospital pharmacy products differ from D2C products; Sat Kartar is developing hospital-specific SKUs in its factory, and bilaterally, each partner’s products can be used in the other’s hospitals.
- Agreement is non-exclusive: Jeena Sikho can open hospitals in South India, and Sat Kartar can open hospitals in North India; complete collaboration details are still being formulated.
Manprit Singh Chadha: “Why would I actually try to invest more in North India, rather than invest in South India and take the expertise and why to reinvent the wheel? Why not let the wheel move forward to South India?”
Revenue Build-Up and Targets
- FY27 ₹300 cr target is product-only and deconstructed: Current run rate ₹225 cr, subsidiaries ₹22 cr, US operations ₹10–15 cr, AI improvement and Ajooni Life Sciences ₹20 cr, leaving ₹30 cr needed from the existing business; management calls this “pretty reasonable.”
- FY28 ₹500 cr path relies on ticket-size growth and new engines: A 15–20% ticket-size jump plus contributions from AI, US, Plantomed and Sat Kartar Life add another 22–25%; exiting FY27 at a ₹30–35 cr monthly run rate already implies a ₹400 cr annualised base.
- Subsidiaries are beginning to fire: Ajooni Life Sciences (nutraceuticals under the Veda bay brand, ticket size ₹900–₹1,200) and Plantomed (low-ticket diabetes) are operational; FY27 subsidiary target is ₹25–30 cr.
- US entry awaits RBI approval: All documentation for direct overseas investment is done; approval could take another 30 days, but operations can start even before equity is subscribed by Sat Kartar Life.
- Geographic growth will come from low-base pockets: Tamil Nadu is the strongest area, North UP another strong area, Madhya Pradesh and Maharashtra are coming up; areas contributing only 5–10% of revenue are where doubling is easiest.
Manprit Singh Chadha: “200 is achieved, 300 and 500 plus must be achieved!”
Margins, Cash and Working Capital
- PAT margin improved from 6% to 9%: The expansion was driven by a 30% semi-variable cost base, of which 12–13% is fixed and gets absorbed as the top line grows.
- FY27 PAT margin target is 11–12%: This applies to the product business moving from ₹200 cr to ₹300 cr revenue.
- Blended margin target of 18–20% by H1 FY28: This includes the hospital contribution, implying a significant step-up once hospital revenue begins.
- Cash generation was weak in H1 but is improving: H1 was hit by the IPO transition, factory build, Plantomed acquisition and inventory buildup; management says most parameters and ratios have stabilised and improved from H1 to H2.
- Inventory days rose 12–15 days: Apart from that, all other working capital parameters improved from H1 to H2.
- Advertisement spend runs at 40–42% of revenue: Management says this will not reduce if the company remains only a product company; the best benchmark could be 38%.
Manprit Singh Chadha: “If cash is not generated, my difference between which has never been the EBITDA to PAT, is going to get screwed.”
AI, Repeat Patients and Operating Levers
- AI has started delivering small-scale results: Test results are “very positive,” and AI has begun improving efficiency and ROI; management cited a 4–5% better ROI from current trials, with further improvement expected as AI scales.
- Repeat patients inched up 1% to 25–26%: A marginal gain that management tracks as a retention metric.
- Factory is now operational: The in-house facility is delivering capsules, though management has no plan to produce all products in-house.
- Subsidiary structure is four entities: Ajooni Life Sciences (nutraceuticals), Plantomed (diabetes), Sat Kartar Ocean (marketing subsidiary, not yet operational), and a pending US company; Ajooni Wellness is a promoter holding company with no business.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue target | Cross ₹300 cr (product business only, excludes hospitals) | FY27 |
| Revenue target | Cross ₹500 cr (product business only, excludes hospitals) | FY28 |
| Hospital break-even | Delhi 30-bed facility breaks even | End of May or June 2026 |
| Hospital bed capacity | 300 beds under Sat Kartar fold (150–200 via Jeena Sikho management) | FY27 end |
| Hospital bed capacity | 1,000 beds | FY28 |
| PAT margin | 11–12% on product business | FY27 (on ₹300 cr base) |
| Blended margin | 18–20% (product + hospital) | H1 FY28 |
| Subsidiary revenue | ₹25–30 cr from subsidiaries | FY27 |
| US subsidiary | Operations begin; RBI approval pending (~30 days) | Operations can start before equity subscription |
| Hospital location finalisation | Identify and finalise locations for next facilities | By June 2026 |
Key Metrics
| Metric | Q4 FY26 |
|---|---|
| Revenue | ₹200+ cr (FY26), +23% YoY |
| EBITDA growth | +73% (FY26) |
| PAT | ₹17 cr (FY26), +74% YoY |
| PAT margin | 8.5% to 9% (FY26), up from 6% in FY25 |
| FY27 revenue guidance | ₹300 cr, excluding hospital revenue |
| FY28 revenue guidance | ₹500 cr, excluding hospital revenue |
| FY27 PAT margin target | 11% to 12% |
| Advertisement spend | 40% of revenue, nothing capitalized |
| Average ticket size | ₹3,250, crossed from ₹3,100; targeting ₹3,500 |
| Repeat patient rate | 25% to 26% |
| Subsidiary revenue | ₹1.2 cr (FY26); FY27 target ₹25–30 cr |
| Hospital beds operational | 30 beds (Delhi), running for 40 days |
| Hospital utilization | Not crossed 10% |
| Hospital daily revenue | ~₹50,000, against breakeven of ₹1L per day |
| Hospital ARPOB target | ₹10,000+ per bed per day |
| Hospital margin at 60% occupancy | 30% to 35% |
| Blended PAT margin target (H1 FY28) | 18% to 20%, including hospital revenue |
| Cash balance for hospital expansion | ₹45 cr |
| AI-driven ROI improvement | 4% to 5% better ROI in trials |